A Novel Approach Utilizing Biofilm Time-Kill Curves To Assess the Bactericidal Activity of Ceftaroline Combinations against Biofilm-Producing Methicillin-Resistant Staphylococcus aureus

被引：40
作者：
Barber, Katie E. [1 ]
Werth, Brian J. [1 ]
McRoberts, John P. [1 ]
Rybak, Michael J. [1 ,2 ]
机构：
[1] Wayne State Univ, Sch Med, Eugene Applebaum Coll Pharm & Hlth Sci, Antiinfect Res Lab, Detroit, MI 48202 USA
[2] John D Dingell Vet Affairs Med Ctr, Detroit, MI USA
来源：
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2014年 / 58卷 / 05期
关键词：
CLINICAL-PRACTICE GUIDELINES; INFECTIOUS-DISEASES SOCIETY; IN-VITRO MODEL; ANTIMICROBIAL AGENTS; DEVICE; DAPTOMYCIN; VANCOMYCIN; MANAGEMENT; DIAGNOSIS; RIFAMPIN;
D O I：
10.1128/AAC.02764-13
中图分类号：
Q93 [微生物学];
学科分类号：
071005 ; 100705 ;
摘要：
Medical device infections frequently require combination therapy. Beta-lactams combined with glycopeptides/lipopeptides are bactericidal against methicillin-resistant Staphylococcus aureus (MRSA). Novel macrowell kill-curve methods tested synergy between ceftaroline or cefazolin plus daptomycin, vancomycin, or rifampin against biofilm-producing MRSA. Ceftaroline combinations demonstrated the most pronounced bacterial reductions. Ceftaroline demonstrated greatest kill with daptomycin (4.02 +/- 0.59 log(10) CFU/cm(2)), compared to combination with vancomycin (3.36 +/- 0.35 log(10) CFU/cm(2)) or rifampin (2.68 +/- 0.61 log(10) CFU/cm(2)). These data suggest that beta-lactam combinations are useful against MRSA biofilms.
引用
收藏
页码：2989 / 2992
页数：4
相关论文
共 25 条
  • [1] American Society for Microbiology, ANTIMICROB AGENTS CH, V52, P1
  • [2] Mutation of sarA in Staphylococcus aureus limits biofilm formation
    Beenken, KE
    Blevins, JS
    Smeltzer, MS
    [J]. INFECTION AND IMMUNITY, 2003, 71 (07) : 4206 - 4211
  • [3] IN-VIVO VERIFICATION OF IN-VITRO MODEL OF ANTIBIOTIC-TREATMENT OF DEVICE-RELATED INFECTION
    BLASER, J
    VERGERES, P
    WIDMER, AF
    ZIMMERLI, W
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1995, 39 (05) : 1134 - 1139
  • [4] The MBEC assay system: Multiple equivalent biofilms for antibiotic and biocide susceptibility testing
    Ceri, H
    Olson, M
    Morck, D
    Storey, D
    Read, R
    Buret, A
    Olson, B
    [J]. MICROBIAL GROWTH IN BIOFILMS, PT B: SPECIAL ENVIRONMENTS AND PHYSICOCHEMICAL ASPECTS, 2001, 337 : 377 - 385
  • [5] The Calgary Biofilm Device: New technology for rapid determination of antibiotic susceptibilities of bacterial biofilms
    Ceri, H
    Olson, ME
    Stremick, C
    Read, RR
    Morck, D
    Buret, A
    [J]. JOURNAL OF CLINICAL MICROBIOLOGY, 1999, 37 (06) : 1771 - 1776
  • [6] ADHERENCE OF COAGULASE-NEGATIVE STAPHYLOCOCCI TO PLASTIC TISSUE-CULTURE PLATES - A QUANTITATIVE MODEL FOR THE ADHERENCE OF STAPHYLOCOCCI TO MEDICAL DEVICES
    CHRISTENSEN, GD
    SIMPSON, WA
    YOUNGER, JJ
    BADDOUR, LM
    BARRETT, FF
    MELTON, DM
    BEACHEY, EH
    [J]. JOURNAL OF CLINICAL MICROBIOLOGY, 1985, 22 (06) : 996 - 1006
  • [7] Biofilms: Survival mechanisms of clinically relevant microorganisms
    Donlan, RM
    Costerton, JW
    [J]. CLINICAL MICROBIOLOGY REVIEWS, 2002, 15 (02) : 167 - +
  • [8] In vitro effects of antimicrobial agents on planktonic and biofilm forms of Staphylococcus lugdunensis clinical isolates
    Frank, Kristi L.
    Reichert, Emily J.
    Piper, Kerryl E.
    Patel, Robin
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2007, 51 (03) : 888 - 895
  • [9] Key role of teichoic acid net charge in Staphylococcus aureus colonization of artificial surfaces
    Gross, M
    Cramton, SE
    Götz, F
    Peschel, A
    [J]. INFECTION AND IMMUNITY, 2001, 69 (05) : 3423 - 3426
  • [10] Bacterial biofilms: From the natural environment to infectious diseases
    Hall-Stoodley, L
    Costerton, JW
    Stoodley, P
    [J]. NATURE REVIEWS MICROBIOLOGY, 2004, 2 (02) : 95 - 108
123